Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Closing Expected On August 26, 2024, With Proceeds To Support Working Capital And Corporate Purposes
Roth MKM analyst Jonathan Aschoff reiterates Nuwellis (NASDAQ:NUWE) with a Buy and maintains $17 price target.
Nuwellis (NASDAQ:NUWE) reported quarterly losses of $(18.85) per share which missed the analyst consensus estimate of $(8.24) b...
Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload (the...
Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated ...
Roth MKM analyst Jonathan Aschoff initiates coverage on Nuwellis (NASDAQ:NUWE) with a Buy rating and announces Price Target ...
